Upexi Enters Agreement for Stock Issuance with Institutional Investor
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 06 2026
0mins
Should l Buy UPXI?
Source: Newsfilter
- Stock Issuance Agreement: Upexi has entered into a definitive agreement with a single institutional investor for the sale of 6,337,000 shares of common stock and warrants, priced at $1.17 per share, expected to close on February 9, 2026, with proceeds allocated for working capital and general corporate purposes.
- Warrant Terms: The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire in five years, with a forced conversion price of $5.00, indicating the company's confidence in future stock price appreciation.
- Existing Warrant Amendments: Upexi has agreed to amend previously issued warrants for 3,289,474 shares from December 2025, reducing the exercise price from $4.00 to $2.83 and the redemption price trigger from $8.50 to $7.00, aimed at enhancing investor appeal.
- Compliance and Registration Statement: The offering is made pursuant to an effective S-3 registration statement declared effective on January 8, 2026, ensuring compliance and providing transparent disclosures to investors, thereby enhancing market trust.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UPXI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UPXI
Wall Street analysts forecast UPXI stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.744
Low
6.00
Averages
6.00
High
6.00
Current: 0.744
Low
6.00
Averages
6.00
High
6.00
About UPXI
Upexi, Inc. is a solana-focused treasury company. The Company is a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space. The Company’s brands include Lucky Tail, PRAX, and Cure Mushrooms. Lucky Tail is a pet care product brand that provides products from grooming tools to nutritional products. Cure Mushrooms is a full line of medicinal mushroom products, designed by effect for consumers, which offers mushroom extracts in tinctures and gummies. PRAX is a full line of medicinal mushroom products, designed by effect for consumers, which are cultivated, extracted, and produced in the United States. Its products are distributed in the United States of America and internationally through multiple entities and managed through locations in Florida.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Upexi (UPXI) Q2 2026 Earnings Call Transcript
See More
Upexi, Inc. Q2 2026 Earnings Call Insights
- Financial Performance Overview: Upexi reported total revenue of approximately $8.1 million for Q2, an increase of about $4 million year-over-year, despite a net loss of approximately $178.9 million primarily due to unrealized losses on digital assets and stock compensation expenses, indicating financial pressure amid market volatility.
- Asset Management Strategy: CEO Allan Marshall emphasized that despite a 40% drop in Solana prices, the company plans to enhance its valuation by increasing Solana token holdings and yields, demonstrating a commitment to stability in uncertain markets.
- Market Risk Mitigation: Management identified market volatility and declining Solana prices as key risks impacting quarterly results, with Marshall mentioning mergers and asset sales as potential mitigants, reflecting the company's adaptive strategies in the face of challenges.
- Future Outlook: Although no specific earnings guidance was provided, management remains optimistic about Solana's long-term potential, planning to increase the number of tokens held in treasury and boost quarterly revenue from the treasury, indicating confidence in market recovery.
See More
Upexi Reports Q2 Loss Driven by Digital Asset Write-Downs
- Quarterly Loss: Upexi reported a Q2 GAAP EPS of -$2.94, primarily driven by $164.5 million in unrealized losses on digital assets, reflecting significant non-cash fair value adjustments that adversely impacted the company's financial health.
- Revenue Growth Pressure: Despite a 102.5% year-over-year revenue increase to $8.1 million, the figure fell short of expectations by $1.32 million, indicating competitive pressures in the market, particularly as revenue from the consumer brands segment totaled only $2.9 million.
- Digital Asset Revenue: Revenue from digital assets, mainly from staking income, reached $5.1 million; however, this performance was insufficient to offset overall financial losses, highlighting the risks associated with the company's reliance on digital assets.
- Financing Activities: Upexi entered into a $36 million convertible note deal backed by Solana with Hivemind Capital and plans to conduct a private placement offering of up to $23 million, aimed at enhancing liquidity and capital structure despite ongoing financial challenges.
See More
UPEXI Reports Q2 EPS of -$2.94
- Market Overview: The U.S. stock market is experiencing fluctuations, with the S&P 500 index showing a slight decline of 2.94 points.
- Economic Indicators: Recent economic data suggests mixed signals, impacting investor sentiment and market performance.
- Sector Performance: Various sectors are reacting differently to economic news, with some showing resilience while others struggle.
- Future Outlook: Analysts are closely monitoring upcoming economic reports that could influence market trends and investor decisions.
See More
UPEXI Reports Q2 Revenue of $8.1 Million
- Company Overview: UPEXIQ reported a revenue of USD 8.1 million for the second quarter.
- Financial Performance: The revenue reflects the company's growth and operational success during this period.
- Market Position: UPEXIQ continues to strengthen its position in the market with increasing financial results.
- Future Outlook: The company is optimistic about future performance and potential growth opportunities.
See More
UPEXI Reports Q2 Net Loss of USD 178.9 Million
- Financial Performance: UPEX reported a net income of USD 178.9 million for the second quarter.
- Comparison to Previous Period: This figure reflects a significant change compared to previous financial results, indicating growth or decline in profitability.
See More
Upexi (UPXI) Q2 2026 Earnings Call Transcript
See More
Upexi, Inc. Q2 2026 Earnings Call Insights
- Financial Performance Overview: Upexi reported total revenue of approximately $8.1 million for Q2, an increase of about $4 million year-over-year, despite a net loss of approximately $178.9 million primarily due to unrealized losses on digital assets and stock compensation expenses, indicating financial pressure amid market volatility.
- Asset Management Strategy: CEO Allan Marshall emphasized that despite a 40% drop in Solana prices, the company plans to enhance its valuation by increasing Solana token holdings and yields, demonstrating a commitment to stability in uncertain markets.
- Market Risk Mitigation: Management identified market volatility and declining Solana prices as key risks impacting quarterly results, with Marshall mentioning mergers and asset sales as potential mitigants, reflecting the company's adaptive strategies in the face of challenges.
- Future Outlook: Although no specific earnings guidance was provided, management remains optimistic about Solana's long-term potential, planning to increase the number of tokens held in treasury and boost quarterly revenue from the treasury, indicating confidence in market recovery.
See More
Upexi Reports Q2 Loss Driven by Digital Asset Write-Downs
- Quarterly Loss: Upexi reported a Q2 GAAP EPS of -$2.94, primarily driven by $164.5 million in unrealized losses on digital assets, reflecting significant non-cash fair value adjustments that adversely impacted the company's financial health.
- Revenue Growth Pressure: Despite a 102.5% year-over-year revenue increase to $8.1 million, the figure fell short of expectations by $1.32 million, indicating competitive pressures in the market, particularly as revenue from the consumer brands segment totaled only $2.9 million.
- Digital Asset Revenue: Revenue from digital assets, mainly from staking income, reached $5.1 million; however, this performance was insufficient to offset overall financial losses, highlighting the risks associated with the company's reliance on digital assets.
- Financing Activities: Upexi entered into a $36 million convertible note deal backed by Solana with Hivemind Capital and plans to conduct a private placement offering of up to $23 million, aimed at enhancing liquidity and capital structure despite ongoing financial challenges.
See More
UPEXI Reports Q2 EPS of -$2.94
- Market Overview: The U.S. stock market is experiencing fluctuations, with the S&P 500 index showing a slight decline of 2.94 points.
- Economic Indicators: Recent economic data suggests mixed signals, impacting investor sentiment and market performance.
- Sector Performance: Various sectors are reacting differently to economic news, with some showing resilience while others struggle.
- Future Outlook: Analysts are closely monitoring upcoming economic reports that could influence market trends and investor decisions.
See More
UPEXI Reports Q2 Revenue of $8.1 Million
- Company Overview: UPEXIQ reported a revenue of USD 8.1 million for the second quarter.
- Financial Performance: The revenue reflects the company's growth and operational success during this period.
- Market Position: UPEXIQ continues to strengthen its position in the market with increasing financial results.
- Future Outlook: The company is optimistic about future performance and potential growth opportunities.
See More
UPEXI Reports Q2 Net Loss of USD 178.9 Million
- Financial Performance: UPEX reported a net income of USD 178.9 million for the second quarter.
- Comparison to Previous Period: This figure reflects a significant change compared to previous financial results, indicating growth or decline in profitability.
See More
